How I treat refractory acute GVHD

Blood

Volumn 109, Issue 10, 2007, Pages 4119-4126

  Deeg, H Joachim ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; BASILIXIMAB; BECLOMETASONE; BUDESONIDE; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INFLIXIMAB; METHOXSALEN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; PENTOSTATIN; PETHIDINE; POLYCLONAL ANTIBODY; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VISILIZUMAB;

ACUTE DISEASE; ARTICLE; ASEPTIC NECROSIS; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CELL TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEVER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERVENTION STUDY; LONG TERM CARE; LYMPHOCYTOPENIA; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; MYCOSIS; OSTEOPENIA; PILOT STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RISK FACTOR; SEIZURE; SURVIVAL; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; VIRUS INFECTION;

EID: 34248356010     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-041889     Document Type: Article

References (66)

1. Lorenz E, Uphoff D, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst. 1951;12:197-201.
2. van Bekkum DW, de Vries MJ. The production of radiation chimaeras. In: Radiation Chimaeras. London, United Kingdom: Logos Press Limited; 1967:20-78.
3. Billingham RE. The biology of graft-versus-host reactions. In: The Harvey Lectures. New York, NY: Academic Press; 1966:21-78.
4. Ferrara JLM, Cooke KR, Deeg HJ, eds. Graft-vs.-Host Disease. 3rd ed. New York, NY: Marcel Dekker; 2005.
5. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
6. Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, et al. Critical role for CCR5 in the function of donor CD4-+CD25+- regulatory T cells during acute graft-versus-host disease. Blood. 2005;106:3300-3307.
7. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756-762.
8. Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood. 2006;108:2485-2492.
9. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med. 2002;8:410-414.
10. Petersdorf EW, Gooley T, Malkki M, Horowitz M. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors: joint report of the IHWG in HCT: Proceedings of the 14th International Histocompatibility Workshop and Conference. Tissue Antigens. In press.
11. Goulmy E, Schipper J, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334:281-285.
12. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004;104:2254-2262.
13. Sullivan KM. Graft-vs.-host disease. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. Oxford, United Kingdom: Blackwell Publishing Ltd; 2004:635-664.
14. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756-762.
15. Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant. 1991;7:193-198.
16. Sala-Torra O, Martin PJ, Storer B, et al. Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and non-myeloablative conditioining regimens [abstract]. Blood. 2006; 108(part 1):227a. Abstract no. 755.
17. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:655-668.
18. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
19. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004;10:178-185.
20. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2005;11:945-956.
21. Deeg HJ, Flowers MED. Acute graft-versus-host disease. In: Treleaven J, Barrett AJ, eds. Practical Stem Cell Transplantation. Edinburgh, United Kingdom: Elsevier. In press.
22. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-1472.
23. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024-1030.
24. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288-2293.
25. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day -5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107:4177-4181.
26. Bertz H, Afting M, Kreisel W, Duffner U, Greinwald R, Finke J. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant. 1999;24:1185-1189.
27. McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology. 1998;115:28-35.
28. McDonald GB, Cruickshank S, Rodell TC, Hockenberry DM. Oral beclamethasone dipropionate (BDP) for gastrointestinal GVHD: a corticosteroid-sparing treatment with improved survival at day -200 [abstract]. Biol Blood Marrow Transplant. 2006;12(suppl 1):1.
29. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 1996;88:824-830.
30. Cragg L, Blazar BR, DeFor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:441-447.
31. Bacigalupo A, Van Lint MT, Frassoni F, et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut. 1983;46:125-132.
32. Doney K, Martin P, Storb R, et al. A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. Exp Hematol. 1985;13:520-524.
33. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-2216.
34. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 2002;99:2712- 2719.
35. Russell JA, Duggan P, Chaudhry AM, et al. Low dose antithymocyte globulin incorporated into GVHD prophylaxis for matched related donor stem cell transplantation results in low morbidity and no mortality from acute GVHD. Blood. 2001;98(suppl 1):661a. Abstract no. 2773.
36. Remberger M, Svahn BM, Mattsson J, Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation. 2004;78:122-127.
37. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560-565.
38. Lopez M, Clarkson MR, Albin M, Sayegh MH , Najafian N. A novel mechanism of action for antithymocyte globulin: induction of CD4+-CD25+-Foxp3+- regulatory T cells. J Am Soc Nephrol. 2006;17:2844-2853.
39. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:40-46.
40. Soiffer RJ, Martin P. T-cell depletion of allogeneic hematopoietic stem cell grafts. In: Atkinson K, Champlin R, Ritz J, Fibbe W, Ljungman P, Brenner MK, eds. Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambridge, United Kingdom: Cambridge University Press; 2004:416-425.
41. Przepiorka D, Phillips GL, Ratanatharathorn V, et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood. 1998;92:4066-4071.
42. Hebart H, Ehninger G, Schmidt H, et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant. 1995;15:891-894.
43. Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody, ABXCBL. Blood. 2001;98:2052-2058.
44. Heslop HE, Benaim E, Brenner MK, et al. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995;346:805-806.
45. MacMillan ML, Couriel D, Weisdorf DJ, et al. A phase II/III multi-center randomized clinicl trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood; prepublished online November 16, 2006, as DOI 10.1182/blood-2006-08-013995.
46. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:465-471.
47. Wandroo F, Auguston B, Cook M, Craddock C, Mahendra P. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant. 2004;34:285-287.
48. Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs. 2002;62:879-889.
49. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357-4363.
50. Lee SJ, Zahrieh D, Agura E, et al. Effect of upfront daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004;104:1559-1564.
51. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:1224-1226.
52. Hervé P, Flesch M, Tiberghien J, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood. 1992;79:3362-3368.
53. Hattori K, Hirano T, Oshimi K, Yagita H, Okumura K. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. Leuk Lymphoma. 2000;38:553-561.
54. Couriel DR, Hicks K, Giralt S, Champlin RE. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation [review]. Curr Opin Oncol. 2000;12:582-587.
55. Giaccone L, McCune JS, Maris MB, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood. 2005;106:4381-4388.
56. Margolis J, Vogelsang G. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease [review]. Semin Oncol. 2000;27:72-77.
57. Foss FM. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation [review. Semin Hematol. 2006;43:S35-S43.
58. Carpenter PA, Sanders JE. Steroid-refractory graft-vs.host disease: past, present and future. Pediatr Transplant. 2003;7(suppl 3):19-31.
59. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001;72:1924-1929.
60. Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant. 2000;26:985-991.
61. Furlong T, Leisenring W, Storb R, et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:206-212.
62. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood. 2000;96:2426-2431.
63. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107:3074-3080.
64. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant. 2005;35:1187-1193.
65. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation [review]. Biol Blood Marrow Transplant. 2006;12:7-12.
66. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-1441.